Engineered Bacterial Biomaterials for Augmenting Adoptive Immune Cell Therapy Against Solid Tumors
Advanced Materials · 2026-03 · 38 (16)
DOI: 10.1002/adma.202522140 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Materials, online erschienen am 15.02.2026. Verfasst von Chaojie Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Advanced Drug Delivery and Release Systems, Liangzhu Laboratory, School of Pharmacy, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Biocompatible Materials, Immunotherapy, Adoptive, Neoplasms, Bacteria. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 155 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, "Pioneer" and "Leading Goose" R&D Program of Zhejiang.
Abstract (Originalsprache)
Adoptive immune cell therapy (ACT) represents one of the most promising strategies in cancer immunotherapy, leveraging genetically engineered immune cells to recognize and eradicate tumor cells with high specificity. Durable remissions have been achieved in hematological malignancies, particularly with CD19‐targeted chimeric antigen receptor T (CAR‐T) cell therapies. However, the efficacy of ACT in solid tumors remains limited due to the immunosuppressive tumor microenvironment, tumor heterogeneity, and poor infiltration and persistence of the effector cells within tumor sites. Bacterial biomaterials, encompassing live bacteria and their acellular platforms, for example, outer membrane vesicles, represent emerging classes of programmable systems capable of reshaping the tumor immune microenvironment. In this review, we briefly illustrate the underlying molecular mechanisms by which bacterial biomaterials remodel the tumor environment and underscore the advances in the use of engineered bacterial biomaterials to enhance the efficacy of ACT in solid tumors, highlighting the underlying basic principles and engineering strategies to augment current adoptive cellular therapies for overcoming their faced dilemmas in solid tumor settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Advanced Drug Delivery and Release Systems, Liangzhu Laboratory, School of Pharmacy, Zhejiang University, Hangzhou, China.
- Department of Hepatobiliary and Pancreatic Surgery the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- ZJU-Pujian Research & Development Centre of Medical Artificial Intelligence for Hepatobiliary and Pancreatic Disease, Hangzhou, China.
- Interdisciplinary Nanoscience Center, Aarhus University, Aarhus, Denmark.
ORCID-Profile: Chaojie Zhu, Hongjun Li
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- "Pioneer" and "Leading Goose" R&D Program of Zhejiang
- Startup Package of Zhejiang University
- European Union's Research and Innovation Program
- Marie Skłodowska-Curie grant agreement
- National Key Research and Development Program of China
Zitieren
APA
Zhu, C., Sun, Z., Wu, Q., Wang, F., Zhang, L., Wang, W., Ding, Y., & Li, H. (2026). Engineered Bacterial Biomaterials for Augmenting Adoptive Immune Cell Therapy Against Solid Tumors. Advanced Materials, 38(16). https://doi.org/10.1002/adma.202522140
Vancouver
Zhu C, Sun Z, Wu Q, Wang F, Zhang L, Wang W, et al. Engineered Bacterial Biomaterials for Augmenting Adoptive Immune Cell Therapy Against Solid Tumors. Advanced Materials. 2026;38(16). doi:10.1002/adma.202522140
BibTeX
@article{Zhu2026,
author = {Zhu, Chaojie and Sun, Zhongquan and Wu, Qing and Wang, Feifan and Zhang, Lingxiao and Wang, Weilin and Ding, Yuan and Li, Hongjun},
title = {Engineered Bacterial Biomaterials for Augmenting Adoptive Immune Cell Therapy Against Solid Tumors},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {16},
doi = {10.1002/adma.202522140}
}
EUVIMED